Johnson & Johnson Partner Contineum Slides as Depression Drug Fails

Key takeaways

• CTNM shares slid sharply after its Phase 2 depression trial failed to meet the primary endpoint, casting doubt on the drug’s future and impacting both companies’ outlooks.
• CTNM shares fell 9.58% to $13.40
• 52‑week range: $8.60 to $17.79
• Key resistance: $15.34

What happened

Contineum Therapeutics (CTNM) shares fell 9.58% to $13.40 after the company announced that its Phase 2 MOONLIGHT‑1 trial for the depression drug JNJ‑5120/PIPE‑307, licensed to Johnson & Johnson (JNJ), missed its primary efficacy endpoint.

Why it matters

The failure to hit the primary endpoint undermines the commercial prospects of the drug, which could delay or cancel future development and affect JNJ’s pipeline value. It also signals potential safety or efficacy concerns that may prompt a reassessment of the partnership terms.

Short-term and longer-term

Short-term. Short‑term traders should watch for a rebound to the 50‑day SMA at $15.34 or a further break below the 200‑day SMA at $13.60, which could trigger a deeper sell‑off.

Longer-term. Over the next few weeks, investors should assess how the missed endpoint affects the projected revenue timeline for JNJ‑5120/PIPE‑307 and whether JNJ will adjust its investment or partnership strategy.